百花医药
(600721)
| 流通市值：23.60亿 | | | 总市值：23.60亿 |
| 流通股本：3.82亿 | | | 总股本：3.82亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 80,698,046.32 | 202,070,585.9 | 64,055,590.14 | 67,838,213.74 |
| 应收票据及应收账款 | 26,971,468.13 | 16,848,667.57 | 27,664,527.32 | 29,889,338.08 |
| 其中：应收票据 | 1,004,014.5 | 400,000 | 2,800,470.44 | 5,933,045.26 |
| 应收账款 | 25,967,453.63 | 16,448,667.57 | 24,864,056.88 | 23,956,292.82 |
| 应收款项融资 | 4,666,925.92 | 3,487,132.12 | - | - |
| 预付款项 | 9,004,893.96 | 5,031,328.63 | 8,746,545.26 | 5,846,675.5 |
| 其他应收款合计 | 4,171,404.26 | 4,550,462.07 | 4,401,693.25 | 4,466,296.53 |
| 存货 | 132,026,260.69 | 124,831,576.68 | 139,136,791.82 | 153,013,364.32 |
| 合同资产 | 191,460,731.19 | 197,309,609.08 | 204,514,292.15 | 191,121,559.17 |
| 其他流动资产 | 10,535,741.57 | 10,638,424.56 | 10,013,542.32 | 9,851,465.39 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 584,415,472.04 | 564,767,786.61 | 550,682,982.26 | 532,176,912.73 |
| 非流动资产: | | | | |
| 长期股权投资 | 59,707,255.46 | 59,742,692.31 | 60,042,664.76 | 56,965,653.24 |
| 其他权益工具投资 | 3,990,651.48 | 3,959,959.1 | 4,099,962.92 | 4,099,962.92 |
| 投资性房地产 | 245,375,300 | 245,375,300 | 244,670,364 | 244,670,364 |
| 固定资产 | 142,516,127.04 | 136,640,027.29 | 138,464,879.92 | 141,513,729.76 |
| 使用权资产 | 1,436,364.07 | 1,549,043.19 | 1,661,722.72 | 2,159,512.47 |
| 无形资产 | 9,597,922.48 | 10,071,259.83 | 10,229,108.49 | 10,656,871.41 |
| 开发支出 | 12,906,785.26 | 10,487,849.93 | 3,321,549.32 | 2,042,712.98 |
| 商誉 | 11,485,077.64 | 11,485,077.64 | 11,485,077.64 | 11,485,077.64 |
| 长期待摊费用 | 2,834,621.94 | 2,985,641.03 | 2,893,023.31 | 3,174,394.17 |
| 递延所得税资产 | 13,823,893.88 | 14,815,017.17 | 14,738,172.92 | 14,969,489.63 |
| 其他非流动资产 | 1,581,114.77 | 130,500 | 2,047,000 | 700,425 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 505,255,114.02 | 497,242,367.49 | 493,653,526 | 492,438,193.22 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,089,670,586.06 | 1,062,010,154.1 | 1,044,336,508.26 | 1,024,615,105.95 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 101,506,631.38 | 100,726,076.25 | 98,100,380.43 | 96,056,731.15 |
| 应付账款 | 101,506,631.38 | 100,726,076.25 | 98,100,380.43 | 96,056,731.15 |
| 合同负债 | 127,668,087.24 | 111,265,807 | 103,167,466.4 | 107,694,377.46 |
| 应付职工薪酬 | 16,510,906.03 | 26,825,446.25 | 21,084,103.68 | 18,041,730.82 |
| 应交税费 | 3,943,101.68 | 3,942,606.64 | 3,200,220.8 | 3,131,522.53 |
| 其他应付款合计 | 57,696,921.47 | 58,979,209.17 | 58,471,619.66 | 59,976,584.62 |
| 应付股利 | 121,146.5 | 121,146.5 | 121,146.5 | 121,146.5 |
| 一年内到期的非流动负债 | 117,824.69 | 443,245.73 | 437,980.85 | 530,092.99 |
| 其他流动负债 | 6,283,548.11 | 6,256,073.8 | 5,986,177.68 | 5,946,934.82 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 313,727,020.6 | 308,438,464.84 | 290,447,949.5 | 291,377,974.39 |
| 非流动负债: | | | | |
| 租赁负债 | 1,398,554.21 | 1,131,377.56 | 1,167,811.29 | 1,751,279.7 |
| 长期应付职工薪酬 | 736,470.53 | 829,513.27 | 852,750.34 | 855,992.9 |
| 预计负债 | 1,097,589.71 | 1,097,589.71 | - | 500,000 |
| 递延收益 | 1,764,131.92 | 1,809,881.92 | 1,931,363.32 | 2,068,038.89 |
| 递延所得税负债 | 41,904,599.4 | 42,087,952.73 | 41,089,722.52 | 40,554,021.74 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 46,901,345.77 | 46,956,315.19 | 45,041,647.47 | 45,729,333.23 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 360,628,366.37 | 355,394,780.03 | 335,489,596.97 | 337,107,307.62 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 381,822,020 | 381,692,645 | 380,951,412 | 378,223,455 |
| 资本公积 | 2,259,188,761.74 | 2,257,585,442.64 | 2,255,688,980.9 | 2,241,770,055.22 |
| 其他综合收益 | 7,324,488.07 | 7,293,795.69 | 7,433,799.51 | 7,433,799.51 |
| 盈余公积 | 5,030,274.41 | 5,030,274.41 | 5,030,274.41 | 5,030,274.41 |
| 未分配利润 | -1,924,323,324.53 | -1,944,986,783.67 | -1,940,257,555.53 | -1,944,949,785.81 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 729,042,219.69 | 706,615,374.07 | 708,846,911.29 | 687,507,798.33 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 729,042,219.69 | 706,615,374.07 | 708,846,911.29 | 687,507,798.33 |
| 负债和股东权益合计 | 1,089,670,586.06 | 1,062,010,154.1 | 1,044,336,508.26 | 1,024,615,105.95 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-27 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |